Open access
72
Views
9
CrossRef citations to date
0
Altmetric
Original Research
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study
Craig LaForce1 North Carolina Clinical Research, Raleigh, NC, USACorrespondence[email protected]
, Gregory Feldman2 South Carolina Pharmaceutical Research, Spartanburg, SC, USA
, Selwyn Spangenthal3 American Health Research, Charlotte, NC, USA
, Joerg H Eckert4 Novartis Pharma AG, Basel, Switzerland
, Michelle Henley5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
, Francesco Patalano4 Novartis Pharma AG, Basel, Switzerland
& Peter D’Andrea5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
show all
Pages 1233-1243
|
Published online: 08 Jun 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.